114 related articles for article (PubMed ID: 15448676)
1. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy.
Vigliotti ML; Dell'Olio M; La Sala A; Romano G; Tartarone A; Mele G; Musto C; Carella AM; Di Renzo N
Hematol J; 2004; 5(5):453-5. PubMed ID: 15448676
[No Abstract] [Full Text] [Related]
2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Bolognesi A; Verusio C; Villa E
Eur J Cancer; 1995 Nov; 31A(12):2008-12. PubMed ID: 8562157
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
O'Neill BP; O'Fallon JR; Earle JD; Colgan JP; Brown LD; Krigel RL
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):663-73. PubMed ID: 7558957
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system lymphomas: progress in chemotherapy and radiotherapy.
Brada M
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):769-71. PubMed ID: 7558971
[No Abstract] [Full Text] [Related]
7. Therapy of PCNSL at the Massachusetts General Hospital with high dose methotrexate and deferred radiotherapy.
Hochberg FH; Tabatabai G
Ann Hematol; 2001; 80 Suppl 3():B111-2. PubMed ID: 11757690
[No Abstract] [Full Text] [Related]
8. Non-hodgkins lymphoma.
Mead G; Woodcock J; Young C
Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
[No Abstract] [Full Text] [Related]
9. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
Burton C; Smith P; Vaughan-Hudson G; Qian W; Hoskin P; Cunningham D; Hancock B; Linch D
Br J Haematol; 2005 Aug; 130(4):536-41. PubMed ID: 16098067
[TBL] [Abstract][Full Text] [Related]
10. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
11. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
Mead GM; Bleehen NM; Gregor A; Bullimore J; Shirley D; Rampling RP; Trevor J; Glaser MG; Lantos P; Ironside JW; Moss TH; Brada M; Whaley JB; Stenning SP
Cancer; 2000 Sep; 89(6):1359-70. PubMed ID: 11002232
[TBL] [Abstract][Full Text] [Related]
12. [The combined chemoradiotherapy of lymphosarcomas].
Kruglova GV; Finogenova IA
Ter Arkh; 1995; 67(10):60-3. PubMed ID: 8779110
[No Abstract] [Full Text] [Related]
13. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan.
Fischer L; Thiel E; Klasen HA; Kirchen H; Jahnke K; Korfel A
Neurology; 2004 May; 62(10):1885-7. PubMed ID: 15159503
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data.
Boiardi A; Silvani A; Valentini S; Salmaggi A; Allegranza A; Broggi G
J Neurol; 1993 Dec; 241(2):96-100. PubMed ID: 7511159
[TBL] [Abstract][Full Text] [Related]
15. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
Ferreri AJ; Verona C; Politi LS; Chiara A; Perna L; Villa E; Reni M
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):169-75. PubMed ID: 20584577
[TBL] [Abstract][Full Text] [Related]
16. [Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Sugimoto T; Matano S; Nishijima H; Kakuta K; Inamura K; Okamura T; Munemoto S; Satoh S
Gan To Kagaku Ryoho; 2007 Jan; 34(1):125-8. PubMed ID: 17220687
[TBL] [Abstract][Full Text] [Related]
17. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Ferreri AJ; Dell'Oro S; Foppoli M; Bernardi M; Brandes AA; Tosoni A; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Ponzoni M; Picozzi P; Caligaris Cappio F; Reni M
Neurology; 2006 May; 66(9):1435-8. PubMed ID: 16682682
[TBL] [Abstract][Full Text] [Related]
18. [The results of the combined chemoradiation treatment of lymphosarcomas corresponding to the degree of its intensity].
Kruglova GV; Finogenova IA; Shramko AF
Ter Arkh; 1991; 63(7):105-9. PubMed ID: 1788785
[TBL] [Abstract][Full Text] [Related]
19. Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients.
Singhal D; Witham TF; Germanwala A; Flickinger JC; Schiff D; Kondziolka D
Can J Neurol Sci; 2002 May; 29(2):147-53. PubMed ID: 12035835
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
